Shares of AtheroGenics took a hit Tuesday afternoon on the news that the company would release highly-anticipated data on AGI-1067 by the end of the first quarter. Investors had bid up the price of the stock on Friday anticipating that the company could announce trial results as early as this week. The experimental drug for arterial plaque is likely to be a big winner if it can demonstrate positive data in the trial. For now, the stock price is a lesson in how quickly a biotech stock can rise--and how quickly it can drop.
- here's the report on AGI-1067 from TheStreet.com
Related Article:
Speculation heats up on fate of AGI-1067. Report